Alzheon also has a treatment for the disease in late-stage clinical trials
Alzheon Inc., a biotechnology startup that has moved a drug for Alzheimer’s disease into late-stage clinical trials, is now also making a bid to better detect the condition.
Framingham, Mass.-based Alzheon has just launched Phase 3 studies of an Alzheimer’s medicine designed to block the formation of toxic clusters in the brain known as amyloid oligomers, which damage neurons in Alzheimer’s patients. The trial is enrolling people genetically prone to Alzheimer’s.
Additionally, through a new agreement with a research institute in the Czech Republic, Alzheon is now also developing a test designed to detect and quantify levels of amyloid oligomers.
Read the full article here